AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

genOway

CR
Bloomberg   ALGEN FP
Biomedical-Genetics  /  France  Web Site   |   Investors Relation
Concepteur et producteur de modèles innovants pour la recherche pharmaceutique et académique
Target
Upside 141%
Price (€) 1.11
Market Cap (€M) 6.64
Perf. 1W: -8.26%
Perf. 1M: -22.9%
Perf. 3M: -30.8%
Perf Ytd: -48.6%
10 day relative perf. to stoxx600: -11.6%
20 day relative perf. to stoxx600: -23.0%